<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197235</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH B- 0811/063-001</org_study_id>
    <nct_id>NCT01197235</nct_id>
  </id_info>
  <brief_title>Effect of Darbepoetin in Contrast-induced Nephropathy</brief_title>
  <official_title>Prevention of Contrast-Induced Nephropathy by Darbepoetin in Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the drug that produce red blood cells is
      effective in the prevention of kidney dysfunction after coronary angiography in patients with
      chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of radiocontrast agent is inevitable in computed tomography or angiography. However,
      contrast agent can aggravate kidney function. Contrast-induced nephropathy (CIN) refers to
      the clinical situation where decreased kidney function after use of contrast. CIN is the 3rd
      most common cause of acute kidney injury in the hospitals. There are a lot of reports that
      death rate is increased in patients with CIN.

      Erythropoietin is an agent that treat anemia. It also has been reported to have a
      tissue-protective effect in the animal experiments.

      In this study, we hypothesized that erythropoietin can reduce the incidence of CIN in
      patients with chronic kidney disease undergoing coronary angiography.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficult to enroll targeted participants
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of contrast-induced nephropathy (CIN)</measure>
    <time_frame>48 hours</time_frame>
    <description>a greater than 25 percent increase in serum Cr or an absolute increase in serum Cr of 0.5 mg/dL within 48 hours after using the contrast agent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum difference in Cr levels before and after CAG(coronary angiography) or PCI(percutaneous coronary intervention)</measure>
    <time_frame>1 month after the intervention</time_frame>
    <description>the maximum difference in Cr levels before and after CAG or PCI, the incidence of AKI requiring renal replacement therapy, length of hospital stay, mortality, myocardial infarction, revascularization, and the occurrence of stroke</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>darbepoetin-α</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isotonic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion of isotonic saline will be performed 1 hour before angiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darbepoetin-α</intervention_name>
    <description>Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography</description>
    <arm_group_label>darbepoetin-α</arm_group_label>
    <other_name>aranesp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotonic saline</intervention_name>
    <description>Infusion of isotonic saline will be performed 1 hour before angiography</description>
    <arm_group_label>isotonic saline</arm_group_label>
    <other_name>0.9% NaCl solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 18 yr

          -  estimated glomerular filtration rate (GFR) &lt; 60 ml/min/1.73m2

        Exclusion Criteria:

          -  Chronic renal replacement therapy (hemodialysis, peritoneal dialysis, continuous renal
             replacement therapy)

          -  Pregnancy or lactation

          -  Use of contrast agent within 1 week

          -  Emergent CAG or PCI

          -  Not recovered from AKI(acute kidney injury)

          -  Use of nephrotoxic drugs within 48 hr

          -  Cardiogenic shock (SBP(systolic blood pressure) &lt; 90 mmHg) or pulmonary edema

          -  Uncontrolled hypertension (SBP ≥ 200 mmHg or DBP(diastolic blood pressure) ≥ 130 mmHg)

          -  History of hypersensitivity to contrast agent

          -  Known allergy or hypersensitivity to EPO(erythropoietin)

          -  Use of EPO within 1 month

          -  Anemia (hemoglobin &lt; 9 g/dL)

          -  Ventilatory care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki Young Na, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Ntional University Bundang Hospital, Seoul National University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital,</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Ki Young Na</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>darbepoetin, chronic kidney disease, coronary angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

